Century Therapeutics (IPSC) Change in Accured Expenses (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Change in Accured Expenses data on file, last reported at -$4.0 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 39.55% year-over-year to -$4.0 million in Q1 2026; TTM through Mar 2026 was -$1.7 million, a 6.41% decrease from a year earlier, with the FY2025 full-year figure at -$4.3 million, down 369.35% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$4.0 million, down from $1.1 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for IPSC reached as high as $2.9 million in Q3 2023 and fell as low as -$6.5 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged -$202470.6 across 5 years, with a median of $707000.0 in 2025.
• Across the five-year window, Change in Accured Expenses sank 310.87% in 2023 and soared 397.06% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.1 million in 2022, then sank by 310.87% to -$2.4 million in 2023, then surged by 221.74% to $2.9 million in 2024, then plunged by 62.87% to $1.1 million in 2025, then tumbled by 466.64% to -$4.0 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$4.0 million in Q1 2026, $1.1 million in Q4 2025, and $443000.0 in Q3 2025.